Our Team

The founding of ALX Oncology was based upon technology invented at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1

ALX Oncology is an independent, private biotechnology company. Since May 2015, we have raised a total of $176 million in funding.

Emma Abellana

Senior Director, Finance and Controller

Melissa Aquino

Executive Assistant

Nathan Caffo

Chief Business Officer

Michael Chang, Ph.D.

Vice President, Operations

Amy Chen

Senior Scientist

Laura Doyle

Scientist

Philip Fanning, Ph.D.

Senior Director, Clinical Science

Abraham Fong

Senior Director, Clinical Development

Danielle Fontaine

Scientific Associate I

Peter García

Chief Financial Officer

Ons Harrabi

Senior Scientist

Declan Hayes

Director of Strategy and Corporate Development

Tracy Kuo, Ph.D.

Director, Biology

Rosalie Manalang

Senior Accountant

Andrew Olson, Ph.D.

Director, Corporate Development

Steffen Pietzke

Vice President, Finance and Chief Accounting Officer

Jaume Pons, Ph.D.

President and Chief Executive Officer

Sophia Randolph, M.D., Ph.D.

Chief Medical Officer

Katherine Ruffner, M.D.

Vice President, Clinical Development

Emma Sangalang

Senior Scientist

Janet Sim, Ph.D.

Vice President, Protein Science

Hank Stern

Vice President, Chemistry, Manufacturing, and Controls

Hong I. Wan, Ph.D.

Chief Scientific Officer

Susan Vermeir

Vice President, Regulatory Affairs

Michael Warner, J.D., Ph.D.

Acting General Counsel

 

Reference

  1. Kipp Weiskopf, et al. Science 341, 88 (2013);
    DOI: 10.1126/science.1238856;
    Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23722425